Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 465, Issue 1-2, Pages 175-186Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2014.02.023
Keywords
Nano carrier; Nano-transfersomes; Transdermal gel; Drug delivery; Stability; Toxicity
Categories
Funding
- University Grants Commission, Government of India [32-136/2006]
- CSIR, India
Ask authors/readers for more resources
The objective was to develop a stable, reproducible and patient non-infringing novel transdermal drug delivery system nano-carrier transdermal gel (NCTG) in combination of partial dose replacement of diclofenac diethylamine (DDEA) by curcumin (CRM). The drug content of gel was 99.30 and 97.57% for DDEA and CRM. Plasma samples were analyzed by liquid chromatography with triple-quadrupole tandem mass spectrometer (LC-MS/MS). Data were integrated with Analyst (TM) and analyzed by WinNonlin; stability parameters were analyzed using Tukey-Kramer multiple comparison test. Its average skin irritation scored 0.49 concluded to be non-irritant, safe for human use and in vivo studies revealed significantly greater extent of absorption and highly significant inhibition (%) of carrageenan induced paw edema. The results also demonstrated that encapsulation of drugs in nano-carrier increases its biological activity due to superior skin penetration potential. Hence, a novel once day transdermal gel of nano-carrier (nano-transfersomes; deformable vesicular) is achieved, to increase systemic availability, subsequent reduction in dose and toxicity of DDEA was developed for the treatment of inflammation. 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available